Globus Medical Q3 sales fall 0.7%, miss estimates; adjusted EPS beats
GMED•Globus Medical's third-quarter sales fell 0.7% year over year to $763.7 million, below the $792.42 million estimate, while adjusted EPS of $1.23 beat the $1.20 estimate. The company lowered its 2026 revenue forecast to $3.09 billion, maintained its adjusted EPS outlook and authorized a $500 million increase to its share repurchase program.
1. Quarterly results
Globus Medical reported third-quarter sales of $763.7 million, down 0.7% year over year and below analysts' $792.42 million estimate. Adjusted earnings per share rose 4.4% to $1.23, beating the $1.20 estimate; net income was $141.2 million.
2. Outlook and segments
The company lowered its 2026 revenue forecast to $3.09 billion from a prior range of $3.18 billion to $3.22 billion, while maintaining its non-GAAP EPS guidance of $4.95 to $5.05. U.S. Spine revenue grew 2%, while Enabling Technologies revenue increased 24%, with 73% more robot and navigation units deployed.
3. Repurchase authorization
Globus Medical authorized a $500 million increase to its share repurchase program. The company attributed higher net income to lower cost of sales and operating expenses.
